Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-Nationa ...

Here’s what investors need to know.Mangoceuticals shares are powering higher. Why is MGRX stock surging?TRT Sales Surge 336%Since launching in mid-December, month-over-month sales for the injectable TRT program have climbed 336%, while customer acquisition costs have fallen 54%, the company said in an update. Management expects TRT to be the primary growth driver as MangoRx expands both injectable and oral options, including its PRIME capsule, powered by Kyzatrex.Telehealth Platform Targets Growing TRT Mark ...

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher Friday after the company announced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy treatment program.Mangoceuticals stock is among today’s top performers. What’s behind MGRX gains?Early Traction Validates $99 Subscription ModelThe company said month-over-month sales of its injectable TRT program increased 336% since launching in mid-December. MangoRx also reported a 54% reduction in customer acquisi ...

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy ...

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292711 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) FORM S-1 REGISTRATION STATEMENT 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 75248 (214 ...

As filed with the Securities and Exchange Commission on January 13, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mangoceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Texas 8099 87-3841292 (State or other jurisdiction of (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 17130 N. Dallas Parkway, Suite 240 Dallas, Texas 7524 ...

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 1% on Friday, while the Dow rose 0.55% to 48,216.43, and the S&P 500 increased by 0.83% to 6,830.85 [1] - Information technology shares rose by 1.6%, while consumer staples stocks fell by 0.4% [1] Company Performance - Nike Inc. shares fell around 10% despite reporting second-quarter revenue of $12.43 billion, exceeding analyst estimates of $12.22 billion, and earnings of 53 cents per share, surpassing estimates of 38 cents per share. The decline in gross margins for the second consecutive quarter contributed to the stock's drop [2] Commodity Market - Oil prices increased by 0.9% to $56.66, gold rose by 0.4% to $4,381.60, silver surged 3.4% to $67.415, and copper gained 1.1% to $5.4955 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.37%, Spain's IBEX 35 Index rising 0.22%, London's FTSE 100 up by 0.61%, Germany's DAX 40 increasing by 0.37%, and France's CAC 40 gaining 0.01% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.03%, Hong Kong's Hang Seng up by 0.75%, China's Shanghai Composite rising 0.36%, and India's BSE Sensex increasing by 0.53% [7] Notable Stock Movements - Autozi Internet Technology shares surged 54% to $2.34 after announcing a $90 million initial equity investment [9] - Amicus Therapeutics shares rose 31% to $14.20 following the announcement of its acquisition by BioMarin for a total equity value of about $4.8 billion, with BioMarin shares up 19% to $61.88 [9] - Lamb Weston Holdings shares dropped 25% to $44.70 after second-quarter results, while BlackBerry shares fell 10% to $3.90 following third-quarter results [9] - Mangoceuticals Inc. shares declined 45% to $0.72 after announcing a $100 million Solana-focused digital asset treasury strategy [9]

Core Viewpoint - Mangoceuticals, Inc. has successfully closed a registered direct offering and a concurrent private placement, raising approximately $2.5 million to support its health and wellness product development and operations [1][3]. Group 1: Offering Details - The transactions involved the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant to purchase one share of Common Stock at an exercise price of $1.4245 [2]. - The offering price per Common Unit was set at $1.295, while the Pre-Funded Unit was priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Aspects - Aegis Capital Corp. served as the exclusive placement agent for the offerings, and the registered direct offering was conducted under an effective shelf registration statement previously filed with the SEC [4]. - The securities sold in the private placement were not registered under the Securities Act and were offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing a range of men's health and wellness products through a secure telemedicine platform, targeting areas such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [7].

Core Insights - Mangoceuticals (MGRX), a Nasdaq-listed company, has announced a partnership with Cube Group to launch a digital asset treasury (DAT) strategy focused on Solana, with a maximum investment of $100 million [1] - The initiative will be executed by a newly formed subsidiary, Mango DAT, and aims to achieve non-dilutive growth through staking and DeFi yields, targeting a return rate between 7% and 20% [1] - The plan will also advance the tokenization of real-world assets (RWA), the financial system for stablecoins, and the expansion path for DAT 2.0 [1]

Core Insights - The company has announced a $100 million Solana-focused digital asset treasury strategy in partnership with Cube Group, aiming to leverage high-yield opportunities for sustainable growth [1][2][11] Group 1: Strategic Initiatives - The initiative positions the company at the forefront of institutional adoption within the Solana ecosystem, focusing on optimized entry points for long-term value creation [2][12] - The strategy is led by Cube Group, which has a proven track record in digital asset treasuries, and will manage custody, execution, and overall strategy for the company [3][4] - The company has filed a trademark application for "MULTI-DAT," indicating its strategic expansion into the digital asset sector, allowing for various financial activities including virtual currency transactions and investment portfolio oversight [5] Group 2: Digital Asset Treasury 2.0 Strategy - The strategy includes evaluating corporate treasury allocations into established digital assets to diversify holdings and enhance balance-sheet efficiency [8] - It explores participation in tokenized real-world assets to gain liquidity and transparency in a regulated environment [8] - The company plans to integrate regulated stablecoins for treasury management and cross-border activities, aiming to streamline operations and advance its core business [8] Group 3: Yield and Growth Model - The strategy aims for annualized SOL staking yields of 7-8%, with active management targeting yields of 8-20% [16] - The company emphasizes a non-dilutive growth model, utilizing Solana's staking mechanisms to enhance shareholder value without diluting existing shares [9][10] - The initiative is designed to generate superior risk-adjusted returns and contribute to the broader adoption of digital assets in mainstream finance [12]